CJC-1295 Q2 2026: what changed this quarter

The second quarter of 2026 brought regulatory noise around CJC-1295 but no new clinical evidence. The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23-24, 2026, to evaluate a batch of peptides for the 503A Bulks List^[1]. Meanwhile, two 2026 peer-reviewed reviews confirmed what the primary literature has said for years: the human evidence behind CJC-1295 remains thin, limited to two small early-phase studies from 2006, and no randomised efficacy trial has been completed since^[2].

The regulatory picture: still unresolved

CJC-1295 has never been approved for human use by any regulator we cover. The FDA has no approved human medicine containing CJC-1295; the only DailyMed listing is a bulk ingredient for veterinary compounding. In late 2023, the FDA assigned a group of peptides to Category 2 of the 503A Bulks List, restricting their use by compounding pharmacies. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr announced on a podcast that roughly 14 of 19 Category 2 peptides would move toward Category 1 status. The April 2026 reorganisation that followed removed 12 peptides from Category 2, but whether CJC-1295 was among them, and what its current compounding status is, depends on which source you read^[1].

What is not in dispute: the BSCG, a third-party certification body, published an explainer in 2026 noting that CJC-1295 "continues to be classified as a developmental drug without approved medical use" and that FDA documentation from December 2024 "references adverse findings in nonclinical studies, including DNA damage in pituitary cells"^[1]. That pituitary-cell finding is from preclinical work, not a human adverse-event report, but it sits in the agency record and will inform any future PCAC evaluation of CJC-1295 specifically. The BSCG's position is that CJC-1295 remains "illegal for human use in 2026 regardless of other ongoing regulatory changes."

The July PCAC agenda covers seven peptides on its first two days: BPC-157, KPV, TB-500, MOTS-C, emideltide, Semax and Epitalon. CJC-1295 is not on the July agenda. A second PCAC meeting is expected before the end of February 2027 for additional peptides^[3]. Even a favourable PCAC recommendation would not constitute an approval; formal rulemaking must follow before compounding is explicitly authorised under section 503A.

What the 2026 reviews found

Two peer-reviewed papers published in 2026 assessed CJC-1295 as part of broader reviews of injectable peptide therapy. Villegas Meza and colleagues, writing in JBJS Reviews, concluded that "growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions"^[2]. Mayfield and colleagues, in the American Journal of Sports Medicine, reported that CJC-1295 combined with ipamorelin "showed significantly improved maximum tetanic tension in murine models" but cautioned that "information regarding the indications, dosing, frequency, and duration of treatment remains unknown"^[4].

Clinical use should be confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols.

Neither review identified a completed Phase 2 or Phase 3 efficacy trial for CJC-1295 in any indication. The entire human dataset remains the two ConjuChem-era pharmacokinetic studies from 2006. Teichman and colleagues reported a half-life of 5.8 to 8.1 days for the with-DAC compound and growth-hormone elevations of 2 to 10 times baseline for six or more days after a single subcutaneous dose^[5]. That finding is 20 years old and has not been followed by a controlled efficacy study in any clinical population.

The with-DAC versus without-DAC problem persists

The naming confusion between CJC-1295 with DAC (the 30-residue albumin-binding compound from the ConjuChem programme) and CJC-1295 without DAC (identical to MOD-GRF(1-29), a short-acting 29-residue peptide) remains unresolved in the supply chain. The two molecules have fundamentally different pharmacokinetics: the with-DAC form has a half-life measured in days, the without-DAC form roughly 30 minutes^[5]. Most online vendors selling "CJC-1295" ship the cheaper without-DAC peptide without disclosing the distinction.

None of the 2026 regulatory activity addresses product identity or labelling standards, so the confusion will persist regardless of how compounding classification resolves. A reader buying "CJC-1295" to chase the multi-day growth-hormone pulse described by Teichman is, in most cases, receiving MOD-GRF(1-29), a short-acting peptide whose dosing logic is completely different. The only way to confirm which molecule is in a vial is a batch-specific certificate of analysis with mass-spectrometry identity confirmation. For a full breakdown of the two molecules and their published data, see the CJC-1295 peptide page.

What we still do not know

The open questions from the start of Q1 are the same open questions at the end of Q2. There is no defensible therapeutic dose-response range for any clinical indication. There is no chronic-dosing safety dataset. There is no completed efficacy trial. The nonclinical pituitary-cell DNA-damage finding flagged by the FDA in December 2024 has not been followed by a carcinogenicity study. Eric Topol, writing in his Ground Truths Substack in July 2025, grouped CJC-1295 with ipamorelin and tesamorelin as growth-hormone-related peptides that "carry the potential risk of cancer" on mechanistic grounds. The available evidence does not let us rule that concern in or out.

When the PCAC does turn to CJC-1295, it will evaluate whether the peptide belongs on the 503A Bulks List for compounding, not whether it is safe and effective as a finished pharmaceutical. Those are different questions. A favourable PCAC recommendation would let licensed pharmacies compound CJC-1295 under physician supervision. It would not constitute an endorsement of efficacy, it would not establish standardised dosing, and it would not create a labelling requirement that distinguishes the with-DAC and without-DAC forms.

Where this lands

Readers following CJC-1295 should watch the July 23-24 PCAC meeting for any signals about which peptides are scheduled next, and monitor the Federal Register for formal rulemaking notices. CJC-1295 remains prohibited in sport under WADA section S2 and is not authorised as a medicine by the EMA, the MHRA, or any national agency we cover. Any decision about whether to consider a growth-hormone secretagogue belongs with a clinician who knows your history.